D. Boral Capital Reaffirms “Buy” Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $9.00 price objective on the stock.

IVVD has been the topic of several other research reports. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. HC Wainwright decreased their target price on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Finally, Morgan Stanley decreased their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Invivyd has a consensus rating of “Buy” and an average target price of $7.89.

Invivyd Stock Down 8.3 %

NASDAQ IVVD opened at $0.36 on Monday. The company’s 50 day moving average is $0.50 and its 200-day moving average is $0.82. Invivyd has a 12-month low of $0.35 and a 12-month high of $5.20. The firm has a market cap of $42.79 million, a P/E ratio of -0.18 and a beta of 0.61.

Insider Buying and Selling

In other news, Director Terrance Mcguire sold 86,545 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $0.48, for a total value of $41,541.60. Following the transaction, the director now owns 3,170,231 shares of the company’s stock, valued at $1,521,710.88. This represents a 2.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have sold 816,466 shares of company stock valued at $423,214. Company insiders own 17.90% of the company’s stock.

Institutional Investors Weigh In On Invivyd

A number of institutional investors have recently made changes to their positions in the business. State Street Corp boosted its stake in shares of Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after purchasing an additional 35,904 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after purchasing an additional 31,992 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Invivyd in the 2nd quarter valued at $421,000. Cubist Systematic Strategies LLC boosted its position in Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after buying an additional 53,499 shares during the period. Finally, Barclays PLC boosted its position in Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after buying an additional 75,780 shares during the period. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.